key: cord-0934517-wyk9aur4
authors: Paradis, S.; Lockamy, E.; Cooper, C. K.; Young, S.
title: Clinical evaluation of the molecular-based BD SARS-CoV-2/Flu for the BD MAX™ System
date: 2021-02-25
journal: nan
DOI: 10.1101/2021.02.23.21251915
sha: a19acce75c3699c22b4ffd61f0111dc0fdb585e0
doc_id: 934517
cord_uid: wyk9aur4

Efficient and accurate assays for the differential diagnosis of COVID-19 and/or influenza (flu) could facilitate optimal treatment for both diseases. Diagnostic performance related to SARS-CoV-2 and Flu A/B detection was characterized for the BD SARS-CoV-2/Flu for BD MAX System (MAX SARS-CoV-2/Flu) multiplex assay in comparison with BD BioGx SARS-CoV-2 Reagents for BD MAX System (BioGx SARS-CoV-2) and the Cepheid Xpert(R) Xpress Flu/RSV (Xpert Flu). Two hundred and thirty-five nasopharyngeal specimens were obtained from external vendors. MAX SARS-CoV-2/Flu had positive percent agreement (PPA) and negative percent agreement (NPA) values for SARS-CoV-2 and Flu A/B that met FDA-EUA acceptance criteria of >95%.

Since the report of the first cluster of COVID-19 cases in December 2019, over 100 million 39

Specimens and assays 79

This study, which was conducted as part of a Food and Drug Administration-Emergency Use BioFire SARS-CoV-2 assays were performed at BD Integrated Diagnostics Solutions; Xpert Flu 94 and Liat Flu assays were performed at TriCore Reference Laboratories. 95 96 Nasopharyngeal specimens for SARS-CoV-2 testing were obtained from New York Biologics, 97

Inc. (Southhampton, NY, USA) and Trans-Hit Bio (Laval, QC, Canada), and nasopharyngeal 98 specimens for Flu A/B testing were obtained from New York Biologics, Inc (Table S1 ). Two 99 hundred and thirty-five (235) nasopharyngeal specimens either in Copan Universal Transport 100 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 25, 2021. criteria for Flu A/B was ≥95% (lower bound of the 95%CI ≥90%). Only compliant and 124 reportable results for both MAX SARS-CoV-2/Flu and comparator assays were included in this 125 analysis. 126 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 25, 2021. (Table S2) 

Characteristics of and Important Lessons From the Coronavirus 227

COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the 228

Chinese Center for Disease Control and Prevention

Coronavirus Resource Center. Mortality Analyses

Estimated Influenza Illness, Medical Visits, Hospitalizations, and Deaths 232 in the United States-2019-2020 Influenza Season

Global influenza strategy 2019-2030. Geneva: World Health Organization

Current Approaches for Diagnosis 253 of Influenza Virus Infections in Humans

What Happens When COVID-19 Collides With Flu Season?

Testing for SARS-CoV-2 257

COVID-19): a systematic review and clinical guide to molecular and serological in-vitro 258 diagnostic assays

Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus 262 culture